APO Research
Talk to an analyst

APO RESEARCH · REPORT

Therapeutic Cancer Vaccines

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Therapeutic Cancer Vaccines Market Outlook and Growth Opportunities 2026

31 December 2025196 pages

Choose your research edition.

Industry ResearchTherapeutic Cancer Vaccines Industry Research Report 2026120 pages · $2,950 USDIndustry Growth & TrendsGlobal Therapeutic Cancer Vaccines Industry Growth and Trends Forecast to 2032101 pages · $3,450 USDMarket StructureGlobal Therapeutic Cancer Vaccines Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Therapeutic Cancer Vaccines Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Therapeutic Cancer Vaccines Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global Therapeutic Cancer Vaccines market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Therapeutic Cancer Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Therapeutic Cancer Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Therapeutic Cancer Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Therapeutic Cancer Vaccines market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Therapeutic Cancer Vaccines market include Merck, GlaxoSmithKline, Bayer, VAXIMM, Northwest Biotherapeutics, Moderna, Mayo Clinic, Avax Technologies and Asterias Biotherapeutics, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Therapeutic Cancer Vaccines market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Therapeutic Cancer Vaccines and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Therapeutic Cancer Vaccines revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Therapeutic Cancer Vaccines market.

Therapeutic Cancer Vaccines Segment by Company

Merck

GlaxoSmithKline

Bayer

VAXIMM

Northwest Biotherapeutics

Moderna

Mayo Clinic

Avax Technologies

Asterias Biotherapeutics

Antigenics

Therapeutic Cancer Vaccines Segment by Type

Non-specific and Cytokine Strategies

Antigen Vaccine

Whole Cell Vaccine

Others

Therapeutic Cancer Vaccines Segment by Application

Breast Cancer

Prostate Cancer

Brain Tumors

Cervical Cancer

Lung Cancer

Bladder Cancer

Others

Therapeutic Cancer Vaccines Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Therapeutic Cancer Vaccines status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Therapeutic Cancer Vaccines key companies, revenue, market share, and recent developments.

3. To split the Therapeutic Cancer Vaccines breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Therapeutic Cancer Vaccines market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Therapeutic Cancer Vaccines significant trends, drivers, influence factors in global and regions.

6. To analyze Therapeutic Cancer Vaccines competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Therapeutic Cancer Vaccines market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Therapeutic Cancer Vaccines and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Therapeutic Cancer Vaccines.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Therapeutic Cancer Vaccines industry.

Chapter 3: Detailed analysis of Therapeutic Cancer Vaccines company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Therapeutic Cancer Vaccines in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Therapeutic Cancer Vaccines in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Therapeutic Cancer Vaccines Industry Trends Table 2. Therapeutic Cancer Vaccines Industry Drivers Table 3. Therapeutic Cancer Vaccines Industry Opportunities and Challenges Table 4. Therapeutic Cancer Vaccines Industry Restraints Table 5. Global Therapeutic Cancer Vaccines Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Therapeutic Cancer Vaccines Revenue Share by Company (2021-2026) Table 7. Global Therapeutic Cancer Vaccines Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Therapeutic Cancer Vaccines Key Company Manufacturing Base & Headquarters Table 9. Global Therapeutic Cancer Vaccines Company, Product Type & Application Table 10. Global Therapeutic Cancer Vaccines Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Therapeutic Cancer Vaccines by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Non-specific and Cytokine Strategies Table 15. Significant Companies of Antigen Vaccine Table 16. Significant Companies of Whole Cell Vaccine Table 17. Significant Companies of Others Table 18. Global Therapeutic Cancer Vaccines Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 19. Global Therapeutic Cancer Vaccines Sales Value by Type (2021-2026) & (US$ Million) Table 20. Global Therapeutic Cancer Vaccines Sales Value by Type (2027-2032) & (US$ Million) Table 21. Global Therapeutic Cancer Vaccines Sales Value Share by Type (2021-2026) Table 22. Global Therapeutic Cancer Vaccines Sales Value Share by Type (2027-2032) Table 23. Significant Companies of Breast Cancer Table 24. Significant Companies of Prostate Cancer Table 25. Significant Companies of Brain Tumors Table 26. Significant Companies of Cervical Cancer Table 27. Significant Companies of Lung Cancer Table 28. Significant Companies of Bladder Cancer Table 29. Significant Companies of Others Table 30. Global Therapeutic Cancer Vaccines Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Therapeutic Cancer Vaccines Sales Value by Application (2021-2026) & (US$ Million) Table 32. Global Therapeutic Cancer Vaccines Sales Value by Application (2027-2032) & (US$ Million) Table 33. Global Therapeutic Cancer Vaccines Sales Value Share by Application (2021-2026) Table 34. Global Therapeutic Cancer Vaccines Sales Value Share by Application (2027-2032) Table 35. Global Therapeutic Cancer Vaccines Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Therapeutic Cancer Vaccines Sales Value by Region (2021-2026) & (US$ Million) Table 37. Global Therapeutic Cancer Vaccines Sales Value Share by Region (2021-2026) Table 38. Global Therapeutic Cancer Vaccines Sales Value by Region (2027-2032) & (US$ Million) Table 39. Global Therapeutic Cancer Vaccines Sales Value Share by Region (2027-2032) Table 40. Global Therapeutic Cancer Vaccines Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 41. Global Therapeutic Cancer Vaccines Sales Value by Country (2021-2026) & (US$ Million) Table 42. Global Therapeutic Cancer Vaccines Sales Value Market Share by Country (2021-2026) Table 43. Global Therapeutic Cancer Vaccines Sales Value by Country (2027-2032) & (US$ Million) Table 44. Global Therapeutic Cancer Vaccines Sales Value Market Share by Country (2027-2032) Table 45. Merck Company Information Table 46. Merck Business Overview Table 47. Merck Therapeutic Cancer Vaccines Revenue (US$ Million) and Gross Margin (2021-2026) Table 48. Merck Therapeutic Cancer Vaccines Product Portfolio Table 49. Merck Recent Development Table 50. GlaxoSmithKline Company Information Table 51. GlaxoSmithKline Business Overview Table 52. GlaxoSmithKline Therapeutic Cancer Vaccines Revenue (US$ Million) and Gross Margin (2021-2026) Table 53. GlaxoSmithKline Therapeutic Cancer Vaccines Product Portfolio Table 54. GlaxoSmithKline Recent Development Table 55. Bayer Company Information Table 56. Bayer Business Overview Table 57. Bayer Therapeutic Cancer Vaccines Revenue (US$ Million) and Gross Margin (2021-2026) Table 58. Bayer Therapeutic Cancer Vaccines Product Portfolio Table 59. Bayer Recent Development Table 60. VAXIMM Company Information Table 61. VAXIMM Business Overview Table 62. VAXIMM Therapeutic Cancer Vaccines Revenue (US$ Million) and Gross Margin (2021-2026) Table 63. VAXIMM Therapeutic Cancer Vaccines Product Portfolio Table 64. VAXIMM Recent Development Table 65. Northwest Biotherapeutics Company Information Table 66. Northwest Biotherapeutics Business Overview Table 67. Northwest Biotherapeutics Therapeutic Cancer Vaccines Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. Northwest Biotherapeutics Therapeutic Cancer Vaccines Product Portfolio Table 69. Northwest Biotherapeutics Recent Development Table 70. Moderna Company Information Table 71. Moderna Business Overview Table 72. Moderna Therapeutic Cancer Vaccines Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. Moderna Therapeutic Cancer Vaccines Product Portfolio Table 74. Moderna Recent Development Table 75. Mayo Clinic Company Information Table 76. Mayo Clinic Business Overview Table 77. Mayo Clinic Therapeutic Cancer Vaccines Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. Mayo Clinic Therapeutic Cancer Vaccines Product Portfolio Table 79. Mayo Clinic Recent Development Table 80. Avax Technologies Company Information Table 81. Avax Technologies Business Overview Table 82. Avax Technologies Therapeutic Cancer Vaccines Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. Avax Technologies Therapeutic Cancer Vaccines Product Portfolio Table 84. Avax Technologies Recent Development Table 85. Asterias Biotherapeutics Company Information Table 86. Asterias Biotherapeutics Business Overview Table 87. Asterias Biotherapeutics Therapeutic Cancer Vaccines Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. Asterias Biotherapeutics Therapeutic Cancer Vaccines Product Portfolio Table 89. Asterias Biotherapeutics Recent Development Table 90. Antigenics Company Information Table 91. Antigenics Business Overview Table 92. Antigenics Therapeutic Cancer Vaccines Revenue (US$ Million) and Gross Margin (2021-2026) Table 93. Antigenics Therapeutic Cancer Vaccines Product Portfolio Table 94. Antigenics Recent Development Table 95. Research Programs/Design for This Report Table 96. Authors List of This Report Table 97. Secondary Sources Table 98. Primary Sources List of Figures Figure 1. Therapeutic Cancer Vaccines Product Image Figure 2. Global Therapeutic Cancer Vaccines Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Therapeutic Cancer Vaccines Market Size (2021-2032) & (US$ Million) Figure 4. Global Therapeutic Cancer Vaccines Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Non-specific and Cytokine Strategies Image Figure 8. Antigen Vaccine Image Figure 9. Whole Cell Vaccine Image Figure 10. Others Image Figure 11. Global Therapeutic Cancer Vaccines Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 12. Global Therapeutic Cancer Vaccines Sales Value Share 2021 VS 2025 VS 2032 Figure 13. Global Therapeutic Cancer Vaccines Sales Value Share by Type (2021-2032) Figure 14. Breast Cancer Image Figure 15. Prostate Cancer Image Figure 16. Brain Tumors Image Figure 17. Cervical Cancer Image Figure 18. Lung Cancer Image Figure 19. Bladder Cancer Image Figure 20. Others Image Figure 21. Global Therapeutic Cancer Vaccines Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 22. Global Therapeutic Cancer Vaccines Sales Value Share 2021 VS 2025 VS 2032 Figure 23. Global Therapeutic Cancer Vaccines Sales Value Share by Application (2021-2032) Figure 24. Global Therapeutic Cancer Vaccines Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 25. Global Therapeutic Cancer Vaccines Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 26. North America Therapeutic Cancer Vaccines Sales Value (2021-2032) & (US$ Million) Figure 27. North America Therapeutic Cancer Vaccines Sales Value Share by Country (%), 2025 VS 2032 Figure 28. Europe Therapeutic Cancer Vaccines Sales Value (2021-2032) & (US$ Million) Figure 29. Europe Therapeutic Cancer Vaccines Sales Value Share by Country (%), 2025 VS 2032 Figure 30. Asia-Pacific Therapeutic Cancer Vaccines Sales Value (2021-2032) & (US$ Million) Figure 31. Asia-Pacific Therapeutic Cancer Vaccines Sales Value Share by Country (%), 2025 VS 2032 Figure 32. South America Therapeutic Cancer Vaccines Sales Value (2021-2032) & (US$ Million) Figure 33. South America Therapeutic Cancer Vaccines Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Middle East & Africa Therapeutic Cancer Vaccines Sales Value (2021-2032) & (US$ Million) Figure 35. Middle East & Africa Therapeutic Cancer Vaccines Sales Value Share by Country (%), 2025 VS 2032 Figure 36. USA Therapeutic Cancer Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. USA Therapeutic Cancer Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. USA Therapeutic Cancer Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Canada Therapeutic Cancer Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Canada Therapeutic Cancer Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Canada Therapeutic Cancer Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Mexico Therapeutic Cancer Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Mexico Therapeutic Cancer Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Mexico Therapeutic Cancer Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Germany Therapeutic Cancer Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Germany Therapeutic Cancer Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Germany Therapeutic Cancer Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. France Therapeutic Cancer Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. France Therapeutic Cancer Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. France Therapeutic Cancer Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. U.K. Therapeutic Cancer Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. U.K. Therapeutic Cancer Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. U.K. Therapeutic Cancer Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Italy Therapeutic Cancer Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Italy Therapeutic Cancer Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Italy Therapeutic Cancer Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Spain Therapeutic Cancer Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Spain Therapeutic Cancer Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Spain Therapeutic Cancer Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Russia Therapeutic Cancer Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Russia Therapeutic Cancer Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Russia Therapeutic Cancer Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Netherlands Therapeutic Cancer Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Netherlands Therapeutic Cancer Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Netherlands Therapeutic Cancer Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Nordic Countries Therapeutic Cancer Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Nordic Countries Therapeutic Cancer Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Nordic Countries Therapeutic Cancer Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. China Therapeutic Cancer Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. China Therapeutic Cancer Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. China Therapeutic Cancer Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. Japan Therapeutic Cancer Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. Japan Therapeutic Cancer Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. Japan Therapeutic Cancer Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. South Korea Therapeutic Cancer Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. South Korea Therapeutic Cancer Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. South Korea Therapeutic Cancer Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. India Therapeutic Cancer Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. India Therapeutic Cancer Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. India Therapeutic Cancer Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Australia Therapeutic Cancer Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Australia Therapeutic Cancer Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Australia Therapeutic Cancer Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Southeast Asia Therapeutic Cancer Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Southeast Asia Therapeutic Cancer Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Southeast Asia Therapeutic Cancer Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Brazil Therapeutic Cancer Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Brazil Therapeutic Cancer Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Brazil Therapeutic Cancer Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Argentina Therapeutic Cancer Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Argentina Therapeutic Cancer Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Argentina Therapeutic Cancer Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Chile Therapeutic Cancer Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Chile Therapeutic Cancer Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Chile Therapeutic Cancer Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Colombia Therapeutic Cancer Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Colombia Therapeutic Cancer Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Colombia Therapeutic Cancer Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Peru Therapeutic Cancer Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Peru Therapeutic Cancer Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Peru Therapeutic Cancer Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Saudi Arabia Therapeutic Cancer Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Saudi Arabia Therapeutic Cancer Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Saudi Arabia Therapeutic Cancer Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Israel Therapeutic Cancer Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Israel Therapeutic Cancer Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Israel Therapeutic Cancer Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. UAE Therapeutic Cancer Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. UAE Therapeutic Cancer Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. UAE Therapeutic Cancer Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Turkey Therapeutic Cancer Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Turkey Therapeutic Cancer Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Turkey Therapeutic Cancer Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Iran Therapeutic Cancer Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Iran Therapeutic Cancer Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Iran Therapeutic Cancer Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Egypt Therapeutic Cancer Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Egypt Therapeutic Cancer Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Egypt Therapeutic Cancer Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Years Considered Figure 121. Research Process Figure 122. Key Executives Interviewed

Scope & coverage.

Types
  • Non-specific and Cytokine Strategies
  • Antigen Vaccine
  • Whole Cell Vaccine
  • Others
Applications
  • Breast Cancer
  • Prostate Cancer
  • Brain Tumors
  • Cervical Cancer
  • Lung Cancer
  • Bladder Cancer
  • Others
Companies covered
  • Merck
  • GlaxoSmithKline
  • Bayer
  • VAXIMM
  • Northwest Biotherapeutics
  • Moderna
  • Mayo Clinic
  • Avax Technologies
  • Asterias Biotherapeutics
  • Antigenics

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Therapeutic Cancer Vaccines Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Therapeutic Cancer Vaccines Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Therapeutic Cancer Vaccines Market Dynamics
  1. 2.1 Therapeutic Cancer Vaccines Industry Trends
  2. 2.2 Therapeutic Cancer Vaccines Industry Drivers
  3. 2.3 Therapeutic Cancer Vaccines Industry Opportunities and Challenges
  4. 2.4 Therapeutic Cancer Vaccines Industry Restraints
3 Therapeutic Cancer Vaccines Market by Company
  1. 3.1 Global Therapeutic Cancer Vaccines Company Revenue Ranking in 2025
  2. 3.2 Global Therapeutic Cancer Vaccines Revenue by Company (2021-2026)
  3. 3.3 Global Therapeutic Cancer Vaccines Company Ranking (2024-2026)
  4. 3.4 Global Therapeutic Cancer Vaccines Company Manufacturing Base and Headquarters
  5. 3.5 Global Therapeutic Cancer Vaccines Company Product Type and Application
  6. 3.6 Global Therapeutic Cancer Vaccines Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Therapeutic Cancer Vaccines Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Therapeutic Cancer Vaccines Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Therapeutic Cancer Vaccines Market by Type
  1. 4.1 Therapeutic Cancer Vaccines Type Introduction
  2. 4.1.1 Non-specific and Cytokine Strategies
  3. 4.1.2 Antigen Vaccine
  4. 4.1.3 Whole Cell Vaccine
  5. 4.1.4 Others
  6. 4.2 Global Therapeutic Cancer Vaccines Sales Value by Type
  7. 4.2.1 Global Therapeutic Cancer Vaccines Sales Value by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Therapeutic Cancer Vaccines Sales Value by Type (2021-2032)
  9. 4.2.3 Global Therapeutic Cancer Vaccines Sales Value Share by Type (2021-2032)
5 Therapeutic Cancer Vaccines Market by Application
  1. 5.1 Therapeutic Cancer Vaccines Application Introduction
  2. 5.1.1 Breast Cancer
  3. 5.1.2 Prostate Cancer
  4. 5.1.3 Brain Tumors
  5. 5.1.4 Cervical Cancer
  6. 5.1.5 Lung Cancer
  7. 5.1.6 Bladder Cancer
  8. 5.1.7 Others
  9. 5.2 Global Therapeutic Cancer Vaccines Sales Value by Application
  10. 5.2.1 Global Therapeutic Cancer Vaccines Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.2.2 Global Therapeutic Cancer Vaccines Sales Value by Application (2021-2032)
  12. 5.2.3 Global Therapeutic Cancer Vaccines Sales Value Share by Application (2021-2032)
6 Therapeutic Cancer Vaccines Regional Value Analysis
  1. 6.1 Global Therapeutic Cancer Vaccines Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Therapeutic Cancer Vaccines Sales Value by Region (2021-2032)
  3. 6.2.1 Global Therapeutic Cancer Vaccines Sales Value by Region: 2021-2026
  4. 6.2.2 Global Therapeutic Cancer Vaccines Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Therapeutic Cancer Vaccines Sales Value (2021-2032)
  7. 6.3.2 North America Therapeutic Cancer Vaccines Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Therapeutic Cancer Vaccines Sales Value (2021-2032)
  10. 6.4.2 Europe Therapeutic Cancer Vaccines Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Therapeutic Cancer Vaccines Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Therapeutic Cancer Vaccines Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Therapeutic Cancer Vaccines Sales Value (2021-2032)
  16. 6.6.2 South America Therapeutic Cancer Vaccines Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Therapeutic Cancer Vaccines Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Therapeutic Cancer Vaccines Sales Value Share by Country, 2025 VS 2032
7 Therapeutic Cancer Vaccines Country-level Value Analysis
  1. 7.1 Global Therapeutic Cancer Vaccines Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Therapeutic Cancer Vaccines Sales Value by Country (2021-2032)
  3. 7.2.1 Global Therapeutic Cancer Vaccines Sales Value by Country (2021-2026)
  4. 7.2.2 Global Therapeutic Cancer Vaccines Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Therapeutic Cancer Vaccines Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Therapeutic Cancer Vaccines Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Therapeutic Cancer Vaccines Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Therapeutic Cancer Vaccines Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Therapeutic Cancer Vaccines Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Therapeutic Cancer Vaccines Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Therapeutic Cancer Vaccines Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Therapeutic Cancer Vaccines Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Therapeutic Cancer Vaccines Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Therapeutic Cancer Vaccines Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Therapeutic Cancer Vaccines Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Therapeutic Cancer Vaccines Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Therapeutic Cancer Vaccines Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Therapeutic Cancer Vaccines Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Therapeutic Cancer Vaccines Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Therapeutic Cancer Vaccines Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Therapeutic Cancer Vaccines Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Therapeutic Cancer Vaccines Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Therapeutic Cancer Vaccines Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Therapeutic Cancer Vaccines Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Therapeutic Cancer Vaccines Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Therapeutic Cancer Vaccines Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Therapeutic Cancer Vaccines Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Therapeutic Cancer Vaccines Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Therapeutic Cancer Vaccines Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Therapeutic Cancer Vaccines Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Therapeutic Cancer Vaccines Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Therapeutic Cancer Vaccines Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Therapeutic Cancer Vaccines Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Therapeutic Cancer Vaccines Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Therapeutic Cancer Vaccines Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Therapeutic Cancer Vaccines Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Therapeutic Cancer Vaccines Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Therapeutic Cancer Vaccines Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Therapeutic Cancer Vaccines Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Therapeutic Cancer Vaccines Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Therapeutic Cancer Vaccines Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Therapeutic Cancer Vaccines Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Therapeutic Cancer Vaccines Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Therapeutic Cancer Vaccines Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Therapeutic Cancer Vaccines Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Therapeutic Cancer Vaccines Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Therapeutic Cancer Vaccines Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Therapeutic Cancer Vaccines Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Therapeutic Cancer Vaccines Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Therapeutic Cancer Vaccines Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Therapeutic Cancer Vaccines Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Therapeutic Cancer Vaccines Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Therapeutic Cancer Vaccines Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Therapeutic Cancer Vaccines Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Therapeutic Cancer Vaccines Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Therapeutic Cancer Vaccines Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Therapeutic Cancer Vaccines Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Therapeutic Cancer Vaccines Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Therapeutic Cancer Vaccines Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Therapeutic Cancer Vaccines Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Therapeutic Cancer Vaccines Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Therapeutic Cancer Vaccines Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Therapeutic Cancer Vaccines Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Therapeutic Cancer Vaccines Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Therapeutic Cancer Vaccines Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Therapeutic Cancer Vaccines Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Therapeutic Cancer Vaccines Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Therapeutic Cancer Vaccines Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Therapeutic Cancer Vaccines Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Therapeutic Cancer Vaccines Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Therapeutic Cancer Vaccines Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Therapeutic Cancer Vaccines Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Therapeutic Cancer Vaccines Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Therapeutic Cancer Vaccines Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Therapeutic Cancer Vaccines Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Therapeutic Cancer Vaccines Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Therapeutic Cancer Vaccines Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Therapeutic Cancer Vaccines Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Therapeutic Cancer Vaccines Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Therapeutic Cancer Vaccines Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Therapeutic Cancer Vaccines Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Therapeutic Cancer Vaccines Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Therapeutic Cancer Vaccines Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Therapeutic Cancer Vaccines Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Therapeutic Cancer Vaccines Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Therapeutic Cancer Vaccines Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Therapeutic Cancer Vaccines Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Therapeutic Cancer Vaccines Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Merck
  2. 8.1.1 Merck Company Information
  3. 8.1.2 Merck Business Overview
  4. 8.1.3 Merck Therapeutic Cancer Vaccines Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Merck Therapeutic Cancer Vaccines Product Portfolio
  6. 8.1.5 Merck Recent Developments
  7. 8.2 GlaxoSmithKline
  8. 8.2.1 GlaxoSmithKline Company Information
  9. 8.2.2 GlaxoSmithKline Business Overview
  10. 8.2.3 GlaxoSmithKline Therapeutic Cancer Vaccines Revenue and Gross Margin (2021-2026)
  11. 8.2.4 GlaxoSmithKline Therapeutic Cancer Vaccines Product Portfolio
  12. 8.2.5 GlaxoSmithKline Recent Developments
  13. 8.3 Bayer
  14. 8.3.1 Bayer Company Information
  15. 8.3.2 Bayer Business Overview
  16. 8.3.3 Bayer Therapeutic Cancer Vaccines Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Bayer Therapeutic Cancer Vaccines Product Portfolio
  18. 8.3.5 Bayer Recent Developments
  19. 8.4 VAXIMM
  20. 8.4.1 VAXIMM Company Information
  21. 8.4.2 VAXIMM Business Overview
  22. 8.4.3 VAXIMM Therapeutic Cancer Vaccines Revenue and Gross Margin (2021-2026)
  23. 8.4.4 VAXIMM Therapeutic Cancer Vaccines Product Portfolio
  24. 8.4.5 VAXIMM Recent Developments
  25. 8.5 Northwest Biotherapeutics
  26. 8.5.1 Northwest Biotherapeutics Company Information
  27. 8.5.2 Northwest Biotherapeutics Business Overview
  28. 8.5.3 Northwest Biotherapeutics Therapeutic Cancer Vaccines Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Northwest Biotherapeutics Therapeutic Cancer Vaccines Product Portfolio
  30. 8.5.5 Northwest Biotherapeutics Recent Developments
  31. 8.6 Moderna
  32. 8.6.1 Moderna Company Information
  33. 8.6.2 Moderna Business Overview
  34. 8.6.3 Moderna Therapeutic Cancer Vaccines Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Moderna Therapeutic Cancer Vaccines Product Portfolio
  36. 8.6.5 Moderna Recent Developments
  37. 8.7 Mayo Clinic
  38. 8.7.1 Mayo Clinic Company Information
  39. 8.7.2 Mayo Clinic Business Overview
  40. 8.7.3 Mayo Clinic Therapeutic Cancer Vaccines Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Mayo Clinic Therapeutic Cancer Vaccines Product Portfolio
  42. 8.7.5 Mayo Clinic Recent Developments
  43. 8.8 Avax Technologies
  44. 8.8.1 Avax Technologies Company Information
  45. 8.8.2 Avax Technologies Business Overview
  46. 8.8.3 Avax Technologies Therapeutic Cancer Vaccines Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Avax Technologies Therapeutic Cancer Vaccines Product Portfolio
  48. 8.8.5 Avax Technologies Recent Developments
  49. 8.9 Asterias Biotherapeutics
  50. 8.9.1 Asterias Biotherapeutics Company Information
  51. 8.9.2 Asterias Biotherapeutics Business Overview
  52. 8.9.3 Asterias Biotherapeutics Therapeutic Cancer Vaccines Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Asterias Biotherapeutics Therapeutic Cancer Vaccines Product Portfolio
  54. 8.9.5 Asterias Biotherapeutics Recent Developments
  55. 8.10 Antigenics
  56. 8.10.1 Antigenics Company Information
  57. 8.10.2 Antigenics Business Overview
  58. 8.10.3 Antigenics Therapeutic Cancer Vaccines Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Antigenics Therapeutic Cancer Vaccines Product Portfolio
  60. 8.10.5 Antigenics Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst